When and how to use maraviroc in HIV-infected patients

AIDS. 2009 Nov 27;23(18):2377-85. doi: 10.1097/QAD.0b013e328332d32d.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • CCR5 Receptor Antagonists*
  • Cyclohexanes / pharmacokinetics
  • Cyclohexanes / therapeutic use*
  • Drug Resistance, Viral / physiology
  • HIV Fusion Inhibitors / pharmacokinetics
  • HIV Fusion Inhibitors / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • HIV-1 / physiology*
  • Humans
  • Maraviroc
  • Triazoles / pharmacokinetics
  • Triazoles / therapeutic use*
  • Viral Tropism / physiology*

Substances

  • CCR5 Receptor Antagonists
  • Cyclohexanes
  • HIV Fusion Inhibitors
  • Triazoles
  • Maraviroc